Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.

Pharmacogenomics - 1 Feb 2016

Cheung Lydia Wt, Mills Gordon B

Abstract excerpt

The regulatory subunit of PI3K, p85α (encoded by PIK3R1), binds, stabilizes and inhibits the PI3K p110 catalytic subunit. Functional characterization of PIK3R1 mutations has identified not only hypomorphs with reduced inhibition of p110, but also hypomorphs and dominant negative mutants that disrupt a novel regulatory role of p85α on PTEN or neomorphs that activate unexpected signaling pathways. The diverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Class Ia Phosphatidylinositol 3-Kinase
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Protein Binding

Share to Protein Multimerization

Share to PTEN Phosphohydrolase

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 26807692
DOI: 10.2217/pgs.15.174
PMCID: PMC5558511

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.PMID 26807692Read ↗

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.Semantic proximity Read ↗

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Semantic proximity Read ↗

Precision Targeting of Mutant PI3Kα.Semantic proximity Read ↗

Should individual PI3 kinase isoforms be targeted in cancer?Semantic proximity Read ↗

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.Semantic proximity Read ↗

Cancer-specific mutations in phosphatidylinositol 3-kinase.Semantic proximity Read ↗

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.Semantic proximity Read ↗

Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.Semantic proximity Read ↗

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.Semantic proximity Read ↗

Oncogenic mutations of PIK3CA in human cancers.Semantic proximity Read ↗

The double life of p85.Semantic proximity Read ↗

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.